全文获取类型
收费全文 | 157262篇 |
免费 | 32995篇 |
国内免费 | 2436篇 |
专业分类
耳鼻咽喉 | 5446篇 |
儿科学 | 5583篇 |
妇产科学 | 2644篇 |
基础医学 | 4341篇 |
口腔科学 | 1867篇 |
临床医学 | 27272篇 |
内科学 | 48894篇 |
皮肤病学 | 7458篇 |
神经病学 | 15761篇 |
特种医学 | 6502篇 |
外科学 | 41570篇 |
综合类 | 247篇 |
现状与发展 | 72篇 |
一般理论 | 5篇 |
预防医学 | 7436篇 |
眼科学 | 3443篇 |
药学 | 1517篇 |
中国医学 | 42篇 |
肿瘤学 | 12593篇 |
出版年
2023年 | 4869篇 |
2022年 | 1248篇 |
2021年 | 3397篇 |
2020年 | 6231篇 |
2019年 | 2417篇 |
2018年 | 7659篇 |
2017年 | 7563篇 |
2016年 | 8684篇 |
2015年 | 8698篇 |
2014年 | 15882篇 |
2013年 | 16097篇 |
2012年 | 6232篇 |
2011年 | 6335篇 |
2010年 | 10747篇 |
2009年 | 14582篇 |
2008年 | 6426篇 |
2007年 | 4584篇 |
2006年 | 6987篇 |
2005年 | 4298篇 |
2004年 | 3505篇 |
2003年 | 2434篇 |
2002年 | 2459篇 |
2001年 | 3804篇 |
2000年 | 3004篇 |
1999年 | 3223篇 |
1998年 | 3676篇 |
1997年 | 3421篇 |
1996年 | 3365篇 |
1995年 | 3233篇 |
1994年 | 1960篇 |
1993年 | 1585篇 |
1992年 | 1363篇 |
1991年 | 1409篇 |
1990年 | 1054篇 |
1989年 | 1181篇 |
1988年 | 1013篇 |
1987年 | 832篇 |
1986年 | 893篇 |
1985年 | 713篇 |
1984年 | 546篇 |
1983年 | 518篇 |
1982年 | 512篇 |
1981年 | 393篇 |
1980年 | 358篇 |
1979年 | 308篇 |
1978年 | 330篇 |
1977年 | 397篇 |
1975年 | 277篇 |
1972年 | 279篇 |
1970年 | 254篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
33.
34.
35.
36.
37.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
38.
Osnat Bairey MD Alisa Taliansky MD Amir Glik MD Alexandra Amiel MD Shlomit Yust-Katz MD Ronit Gurion MD Miri Zektser MD Tzvika Porges MD Nadav Sarid MD Netanel A. Horowitz MD Tzahala Tzuk Shina MD Eyal Lebel MD Amos Cohen MD Karyn Revital Geiger MD Pia Raanani MD Ofir Wolach MD Tali Siegal MD 《Cancer》2023,129(24):3905-3914
39.
The advent of precision medicine has changed the landscape of oncologic biomarkers, drug discovery, drug development, and, more importantly, outcomes for patients with cancer. Precision oncology entails the genomic profiling of tumors to detect actionable aberrations. The advances in clinical next-generation sequencing from both tumor tissue and liquid biopsy and availability of targeted therapies has rapidly entered mainstream clinical practice. In this review, recent major developments in precision oncology that have affected outcomes for patients with cancer are discussed. Rapid clinical development was seen of targeted agents across various mutational profiles such as KRASG12C (which was considered “undruggable” for almost 4 decades), Exon 20 insertions, and RET mutations. Approaches to precision chemotherapy delivery by the introduction of antibody drug conjugates in the armamentarium against lung cancer has been appreciated. 相似文献
40.
- Children with cancer receive many medications outside the hospital administered by their caregivers.
- The study by Walsh et al. shows the number and types of medication errors in these patients. The study includes data from three different centers.
- Importantly, the study shows the types of errors that cause harm. The authors describe how the harmful errors can be prevented.
- We suggest ways these results can be used to identify which patients and families will benefit from additional attention. Providing more help at clinic and in the home may help prevent harmful medication errors in children with cancer.